Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492024 | 0.87 | FFAR1 (0.55) | FFAR1HSD17B10ALDH1A1MAPK1HPGD | |
| SCHEMBL15426812 | 0.84 | MAPT (0.55) | FFAR1HSD17B10ALDH1A1MAPK1HPGD | |
| SCHEMBL9458376 | 0.84 | FFAR1 (0.52) | FFAR1HSD17B10ALDH1A1MAPK1HPGD | |
| SCHEMBL9034251 | 0.83 | FFAR1 (0.65) | FFAR1HSD17B10ALDH1A1MAPK1HPGD | |
| SCHEMBL7667895 | 0.83 | MAPT (0.51) | HSD17B10ALDH1A1MAPK1HPGDALOX15 | |
| SCHEMBL6239095 | 0.82 | MAPT (0.54) | HSD17B10ALDH1A1MAPK1HPGDALOX15 | |
| SCHEMBL7663822 | 0.81 | APEX1 (0.69) | HSD17B10ALDH1A1MAPK1HPGDALOX15 | |
| SCHEMBL30525079 | 0.81 | APEX1 (0.69) | HSD17B10ALDH1A1MAPK1HPGDALOX15 | |
| SCHEMBL874798 | 0.81 | MAPT (0.53) | HSD17B10ALDH1A1MAPK1HPGDALOX15 | |
| SCHEMBL15549840 | 0.81 | HSD17B10 (0.57) | HSD17B10ALDH1A1HPGDRXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730805-B2 | LABELLED DEUTERATED 13C ARYLTHIO ALKANOL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-04 | — | — | US | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-11779665-B2 | Electrochemical flash fluorination and radiofluorination | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-10 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230142087-A1 | LAMINATE | FUJIFILM CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| EP-0301877-A1 | A method of deprotection of 3-amino azetidinones | ELI LILLY AND COMPANY (US) | 1989-02-01 | — | — | EP | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4399146-A | Treatment of atherosclerosis with khellin-related furochromones | THE UPJOHN COMPANY (US) | 1983-08-16 | — | — | US | disclosed |
| US-4313881-A | 5-Hydroxyfurochromones | THE UPJOHN COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4313882-A | 7-Methyl-6-methylthio-, methylsulfinyl-, and methylsulfonyl-methyl-furochromones | THE UPJOHN COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4313883-A | ANTHIATHEROSCLEROSIS | THE UPJOHN COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304722-A | Benzo[1,2-b:5,4-b']difuran-3(2H)-ones | THE UPJOHN COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
| US-4284569-A | Antiatherosclerotic furochromones | THE UPJOHN COMPANY (US) | 1981-08-18 | — | — | US | disclosed |
| US-4281013-A | Antiatherosclerotic use of khellin and khellinin | THE UPJOHN COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | FFAR1 323/4885HSD17B10 34/4885ALDH1A1 2155/4885 |
| US-11779665-B2 | Electrochemical flash fluorination and radiofluorination | FOS, SLCO2A1, COXFA4 | FFAR1 626/4885HSD17B10 1415/4885ALDH1A1 922/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | FFAR1 306/4885HSD17B10 32/4885ALDH1A1 2121/4885 |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | FFAR1 306/4885HSD17B10 32/4885ALDH1A1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.